



Date: 1 August 2024

Private and confidential

Policy Plan: [Name of the Policy Plan] (the “Plan”)  
Policy Number: [Policy Number of the Policy Holder]

Dear Valued Customer,

***As an important notice, please read this letter carefully and seek independent professional advice should you have any questions about the content. Heng An Standard Life (Asia) Limited accepts responsibility for the accuracy of the content of this letter.***

**Changes to the underlying funds corresponding to the investment choices of JPMorgan Funds**

Capitalised terms in this letter have the same meaning as in the offering document of the underlying funds under JPMorgan Funds unless otherwise specified.

Reference code	Name of investment choice
01JU	JPMorgan ASEAN (acc) - USD
06JU	JPMorgan Asia Growth Fund (acc) – USD
17JU	JPMorgan China A-Share Opportunities Fund (acc) - USD
02JU	JPMorgan India (acc) - USD
03JU	JPMorgan Korea (acc) - USD
12JU	JPMorgan Pacific Technology (acc) – USD
D17J	JPMorgan China Income (mth) - RMB (hedged)
D54J	JPMorgan Asia Equity High Income Fund - (mth) - USD

(Each “Investment Choice” and collectively, the “Investment Choices”)

We have been informed by JPMorgan Funds (Asia) Limited (“JPMorgan”), the Hong Kong representative of JPMorgan Funds of the following changes to the underlying funds corresponding to the Investment Choices (each an “Underlying Fund” and collectively, the “Underlying Funds”) effective from 31 July 2024 (the “Effective Date”). As the unitholders of the Investment Choice(s), the following changes applicable to the Underlying Fund(s) may have implications for your investment.

**1. Update to the maximum limit of investment in instruments with loss absorption features for underlying fund corresponding to JPMorgan China Income (mth) - RMB (hedged)**

Currently, the Underlying Fund may invest in instruments with loss absorption features (e.g. contingent convertible securities and certain types of senior non-preferred debt) (“LAP”) up to the limits stated in the offering documents of the Underlying Fund.

Following JPMorgan's internal review, the Manager has decided to increase the Underlying Fund's maximum limit of investment in LAP to the level stated below with effect from 31 July 2024.

<b>Existing maximum exposure to LAP</b>	<b>New maximum exposure to LAP</b>
Up to 10% of its total NAV	Up to 20% of its total NAV

Debt instruments with loss absorption features may be subject to greater risks when compared to traditional debt instruments as such instruments are subject to the risk of being written down or converted to ordinary shares. This has been observed as a measure adopted by regulators to resolve financial difficulty (if any) of major financial institutions.

Please refer to the offering documents for details of the risks associated with debt instruments with loss absorption features.

The Manager believes that the above change does not amount to a material change to the Underlying Fund as there will be no material change or increase in the overall risk profile of the Underlying Fund following the change and the change does not have any material adverse impact on unitholder's rights or interests.

## **2. Enhancement of disclosures in the offering documents of the Underlying Funds**

Other enhancement of disclosures and miscellaneous amendments have been made in the offering documents of the Underlying Funds, including:

- update to the list of directors of JPMorgan Funds (Asia) Limited; and
- other general updates.

The offering documents of the Underlying Funds, which have been revised to reflect the above updates are available at the website of JPMorgan [am.jpmorgan.com/hk](http://am.jpmorgan.com/hk)<sup>1</sup>.

### **Actions to take**

You do not have to take any action if you wish to remain invested in the Investment Choices regardless of the above change. Otherwise you may wish to consider switching the units of the Investment Choices or redirect future regular premiums/contributions (if applicable) to other investment choice(s) through the usual application procedure. No switching fee(s) will be incurred under the current fee structure of your policy.

Investment involves risks. For details regarding the Plan, the investment choices available under the Plan and the underlying funds corresponding to such investment choices (including, without limitation, the investment objectives and policies, risk factors and charges), please refer to the latest offering documents of the Plan (in particular the document named "Investment Choices Brochure") and the offering documents of the underlying funds, all of which are available from us upon request and free of charge. You may also visit our website at [www.hengansl.com.hk](http://www.hengansl.com.hk) for investment choices details.

Should you have any queries, please contact your Financial Adviser or our Customer Service Hotline on +852 2169 0300 or email us at [cs@hengansl.com.hk](mailto:cs@hengansl.com.hk).

Yours faithfully,  
Customer Service Department  
Heng An Standard Life (Asia) Limited

---

<sup>1</sup> The website has not been reviewed by the Securities and Futures Commission.

## 私人及機密

保單計劃：[保單計劃名稱]（「計劃」）  
保單編號：[保單持有人的保單編號]

親愛的客戶

**此乃重要通知，請細閱本信件內容，如對其內容有任何疑問應諮詢獨立專業人士之意見。恒安標準人壽(亞洲)有限公司對本信件內容的準確性負責。**

### 有關連繫至摩根基金之投資選擇的相連基金之若干變更

除非另有指明，否則本信件內使用的術語應與摩根基金內的相連基金的銷售文件所載者具有相同的涵義。

參考編號	投資選擇名稱
01JU	摩根東協(美元)-(累計)
06JU	摩根亞洲增長基金(美元)(累計)
17JU	摩根中國A股機會基金(美元)(累計)
02JU	摩根印度(美元)(累計)
03JU	摩根南韓(美元)(累計)
12JU	摩根太平洋科技(美元)(累計)
D17J	摩根中國入息基金-(每月派息)人民幣對沖
D54J	摩根亞洲股票高息基金-(每月派息)美元

(各稱為「該投資選擇」，統稱為「該等投資選擇」)

我們接獲摩根基金之香港代表 - 摩根基金(亞洲)有限公司(「摩根」)的通知，有關連繫至該等投資選擇的相連基金(各稱為「該相連基金」，統稱為「該等相連基金」)作出的下列變更，由2024年7月31日(「生效日期」)(包括該日在內)起生效。作為該(等)投資選擇的單位持有人，以下有關該(等)相連基金的更新對您的投資或會有所影響。

#### 1. 更新連繫至摩根中國入息基金-(每月派息)人民幣對沖的相連基金於具有吸收虧損特點的工具的最高投資限額

現時，該相連基金可投資於具有吸收虧損特點的工具(例如或然可換股證券及若干類型的高級非優先債務)(「LAP」)，最多達有關該相連基金的銷售文件內所載限額。

經摩根的內部檢視後，經理人已決定由2024年7月31日起將有關該相連基金於LAP的最高投資限額提高至下文所載水平。

於LAP的現有最高投資額	於LAP的新最高投資額
其總資產淨值最多10%	其總資產淨值最多20%

與傳統債務工具相比，具有吸收虧損特點的債務工具可能承受更高風險，因為該等工具須承受被撇減或轉換為普通股的風險。這被視為監管機構為解決主要金融機構的財務困難(如有)所採取的措施。請參閱銷售文件，了解與具有吸收虧損特點的債務工具相關的風險之詳情。

經理人認為，由於變更後有關該相連基金的整體風險取向將不會有重大改變或增加，上述變更並不構成有關該相連基金的重大變更，及變更不會對投資者的權利或利益構成任何重大不利影響。

#### 2. 加強該等相連基金的銷售文件的披露

該等相連基金的銷售文件已作出其他加強披露及雜項修訂，包括：

- 更新摩根基金(亞洲)有限公司之董事名單；及
- 其他一般更新。

該等相連基金的銷售文件已作出修改，以反映上述更新，可於摩根的網頁 [am.jpmorgan.com/hk](http://am.jpmorgan.com/hk)<sup>1</sup>查閱。

<sup>1</sup> 此網頁並未經證券及期貨事務監察委員會審閱。

## 應採取的行動

若您欲在上述變動後繼續投資該等投資選擇，您毋須採取任何行動。否則，您可透過一般的申請程序，要求將在該等投資選擇的單位或日後的定期保費/供款(如適用)轉至其他投資選擇。根據您保單內之現時收費機制，投資選擇的轉換將不會被收取任何轉換費用。

投資涉及風險，有關保單計劃、於保單計劃內可供銷售的投資選擇及連繫至投資選擇的該等相連基金的詳細資料(包括但不限於任何投資選擇的投資目標及政策，風險因素及費用)，您可參閱保單計劃的最新銷售文件(尤其是名為「投資選擇刊物」的文件)及該等相連基金的銷售文件，這些文件可按要求向我們索取並不收取費用。亦可同時瀏覽我們的網頁 [www.hengansl.com.hk](http://www.hengansl.com.hk)。

如有任何查詢，請與您的理財顧問聯絡。您亦可以致電我們的客戶服務熱線+852 2169 0300 或電郵至 [cs@hengansl.com.hk](mailto:cs@hengansl.com.hk) 與我們聯絡。

恒安標準人壽(亞洲)有限公司  
客戶服務部  
謹啟

日期: 2024年8月1日